Arcellx, Inc and Kite, a Gilead Company (NASDAQ: GILD), have expanded their collaboration, initially disclosed in December 2022. In this development, Kite has opted to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, designed for multiple myeloma, with a focus on BCMA. Furthermore, the collaboration scope has widened to include lymphomas for Arcellx's CART-ddBCMA.
Arcellx, expressed enthusiasm about the rapid progress of the partnership and the potential of their innovative synthetic binder, the D-Domain, in creating a new category of CAR T therapies. The deepened collaboration involves Kite's investment in ACLX-001 and increased support for CART-ddBCMA, aiming to extend Arcellx's cash position until 2027.
Kite, highlighted the positive momentum of the CART-ddBCMA program and the extension of the collaboration into areas of significant unmet medical need. Kite's increased engagement aims to advance CART-ddBCMA, strengthen the multiple myeloma pipeline, and explore possibilities in lymphoma.
Arcellx will receive a $200 million equity investment, extending its financial runway. Gilead's estimated ownership in Arcellx will be 13%. The transaction includes an $85 million upfront non-dilutive cash payment, potential milestone payments, and is expected to close by the end of 2023, pending regulatory approvals.
The collaboration between Arcellx and Kite is centered on co-developing and co-commercializing CART-ddBCMA for relapsed or refractory multiple myeloma. The asset utilizes the D-Domain to enhance target specificity and binding affinity. Kite will lead commercialization efforts outside the U.S.
The transaction is anticipated to impact Gilead's 2023 EPS by approximately $0.09-$0.11 per share, and legal counsel to Arcellx is provided by Wilson Sonsini Goodrich & Rosati.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!